Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Reversal Intervention for Metabolic Syndrome Study (TRIMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01043770
Recruitment Status : Completed
First Posted : January 7, 2010
Last Update Posted : January 30, 2020
Sponsor:
Collaborator:
University Hospitals, Leicester
Information provided by (Responsible Party):
University of Leicester

Brief Summary:
The aim of our study is to see if people with metabolic syndrome who attend a group education programme based on lifestyle changes (dietary and increased physical activity) can lessen their risk of having diabetes, heart disease and strokes in the future.

Condition or disease Intervention/treatment Phase
Metabolic Syndrome Behavioral: Group lifestyle education Not Applicable

Detailed Description:

People who have a combination of risk factors termed metabolic syndrome are at increased risk of developing diabetes, heart disease and strokes. Metabolic syndrome is a major public health concern requiring urgent action because 25% of the adult UK population fulfil the criteria, and this will increase as people continue to be less active and levels of overweight and obesity rise.

The aim of our study is to see if people with metabolic syndrome who attend a structured group education programme based on lifestyle changes (dietary and increased physical activity) can lessen their risk of having diabetes and cardiovascular disease in the future. Overall, we hope to show that this type of education reduces the number of people who have metabolic syndrome.

Subjects recruited with metabolic syndrome will be randomised to intervention or control arms. The intervention arm will receive group education and the control group will receive routine care.

The results will inform primary prevention strategies in people from varied ethnic backgrounds who are at high risk of developing type-2 diabetes and cardiovascular disease.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 82 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomised Controlled Trial to Investigate the Effects of a Structured Self-management Education Programme for People With Metabolic Syndrome
Study Start Date : August 2009
Actual Primary Completion Date : August 2011
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group lifestyle education
Multi-component behaviour change intervention
Behavioral: Group lifestyle education
Structured group education programme based on lifestyle changes (dietary and increased physical activity)

No Intervention: Routine care
Routine care



Primary Outcome Measures :
  1. The proportion of people in the intervention and control groups with prevalent metabolic syndrome according to the IDF criteria. [ Time Frame: 12 months follow-up. ]

Secondary Outcome Measures :
  1. The prevalence of metabolic syndrome according to NCEP criteria [ Time Frame: Compared at baseline versus 12 months, and for the intervention group versus the control group ]
  2. Changes in individual components of the metabolic syndrome (fasting plasma glucose, triglycerides, HDL cholesterol, blood pressure, waist circumference), and 2 hour glucose [ Time Frame: Compared at baseline versus 12 months, and for the intervention group versus the control group ]
  3. Changes in biomarkers (hs-CRP, adiponectin, and insulin) [ Time Frame: Compared at baseline versus 12 months, and for the intervention group versus the control group ]
  4. Changes in physical activity as measured by IPAQ and pedometer [ Time Frame: Compared at baseline versus 12 months, and for the intervention group versus the control group ]
  5. Changes in dietary/nutritional intake measured by DINE [ Time Frame: Compared at baseline versus 12 months, and for the intervention group versus the control group ]
  6. Changes in Framingham risk score [ Time Frame: Compared at baseline versus 12 months, and for the intervention group versus the control group ]
  7. Changes in quality of life as measured by EuroQol EQ-5D [ Time Frame: Compared at baseline versus 12 months, and for the intervention group versus the control group ]
  8. Changes in depression/anxiety as measured by HADS [ Time Frame: Compared at baseline versus 12 months, and for the intervention group versus the control group ]
  9. Changes in general self-efficacy as measured by GSE [ Time Frame: Compared at baseline versus 12 months, and for the intervention group versus the control group ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged 40 - 74 years inclusive
  • Registered with a general practice in Leicester City or Leicester County Primary Care Trust
  • Availability of data to allow diagnosis of MetS (IDF criteria) collected at a screening visit

Exclusion Criteria:

  • Previous diagnosis of T2DM, CVD (stroke/cerebrovascular accident, transient ischaemic attack), peripheral arterial disease, or coronary heart disease (angina, myocardial infarction, coronary artery bypass surgery, angioplasty)
  • Life-limiting terminal illness
  • Pregnancy and/or breast feeding
  • Lack of capacity to give informed consent because of serious mental health problems or learning disability.
  • People who are housebound
  • Patients residing in nursing/care homes
  • Individuals who are unable to speak and understand English. (The intervention will be made appropriate for ethnically diverse populations, but individuals who are unable to understand, speak and read English will be excluded at this stage. However, if the self-management programme is found to be successful we would adapt it for non-English speakers.)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01043770


Locations
Layout table for location information
United Kingdom
University of Leicester
Leicester, United Kingdom, LE9 6PE
Sponsors and Collaborators
University of Leicester
University Hospitals, Leicester
Investigators
Layout table for investigator information
Principal Investigator: Kamlesh Khunti, MD, FRCGP Diabetes Research Centre, University of Leicester
Principal Investigator: Melanie J Davies, MD, FRCP Diabetes Research Centre, University of Leicester
Publications of Results:
Layout table for additonal information
Responsible Party: University of Leicester
ClinicalTrials.gov Identifier: NCT01043770    
Other Study ID Numbers: 0025
First Posted: January 7, 2010    Key Record Dates
Last Update Posted: January 30, 2020
Last Verified: December 2011
Keywords provided by University of Leicester:
Metabolic syndrome
Primary prevention
Diabetes
Cardiovascular disease
Patient education
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Syndrome
Disease
Pathologic Processes
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases